×
About 516,611 results
Screening for Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults: U...
https://doi.org/10.1001/jama.2018.14741
JAMA , Curry SJ et. al.

Oct 25th, 2018 - Intimate partner violence (IPV) and abuse of older or vulnerable adults are common in the United States but often remain undetected. In addition to the immediate effects of IPV, such as injury and death, there are other health consequences, many with long-term effects, including development of mental health conditions such as depression, posttraumatic stress disorder, anxiety disorders, substan...

IVF Transfer of Fresh or Frozen Embryos in Women without Polycystic Ovaries.
https://doi.org/10.1056/NEJMoa1703768
The New England Journal of Medicine; Vuong LN, Dang VQ et. al.

Jan 10th, 2018 - Among women who are undergoing in vitro fertilization (IVF), the transfer of frozen embryos has been shown to result in a higher rate of live birth than the transfer of fresh embryos in those with infertility associated with the polycystic ovary syndrome. It is not known whether frozen-embryo transfer results in similar benefit in women with infertility that is not associated with the polycysti...

History of breast feeding and risk of incident endometriosis: prospective cohort study.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574033
BMJ (Clinical Research Ed.); Farland LV, Eliassen AH et. al.

Aug 30th, 2017 - Objective To investigate the association between lifetime breast feeding, exclusive breast feeding, postpartum amenorrhea, and incidence of endometriosis among parous women.Design Prospective cohort study.Setting Nurses' Health Study II, 1989-2011.Participants 72 394women who reported having one or more pregnancies that lasted at least six months, 3296 of whom had laparoscopically confirmed end...

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
https://doi.org/10.1056/NEJMoa1706450
The New England Journal of Medicine; Robson M, Im SA et. al.

Jun 5th, 2017 - Olaparib is an oral poly(adenosine diphosphate-ribose) polymerase inhibitor that has promising antitumor activity in patients with metastatic breast cancer and a germline BRCA mutation. We conducted a randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation and human epidermal growth factor receptor type 2 (...

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
https://doi.org/10.1056/NEJMoa1612645
The New England Journal of Medicine; Masuda N, Lee SJ et. al.

May 31st, 2017 - Patients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer have poor prognoses. The benefit of adjuvant chemotherapy in these patients remains unclear. We randomly assigned 910 patients with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy (containing anthracyc...

Hair dye and chemical straightener use and breast cancer risk in a large US population of black and white women
https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.32738
International Journal of Cancer; Carolyn E. Eberle et al

Dec 4th, 2019 - Many hair products contain endocrine‐disrupting compounds and carcinogens potentially relevant to breast cancer. Products used predominately by black women may contain more hormonally‐active compounds. In a national prospective cohort study, we examined the association between hair dye and chemical relaxer/straightener use and breast cancer risk by ethnicity.

Hereditary Cancer Syndromes and Risk Assessment ACOG COMMITTEE OPINION, Number 793
https://journals.lww.com/greenjournal/Fulltext/2019/12000/Hereditary_Cancer_Syndromes_and_Risk_Assessment_.39.aspx
Obstetrics & Gynecology; ACOG

Nov 30th, 2019 - A hereditary cancer syndrome is a genetic predisposition to certain types of cancer, often with onset at an early age, caused by inherited pathogenic variants in one or more genes. Most hereditary cancer syndromes exhibit autosomal dominant inheritance. The most common hereditary cancer syndromes related to women’s cancer include hereditary breast and ovarian cancer syndrome, Lynch syndrome, Li...

Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines
https://annals.org/aim/fullarticle/2756145/breast-cancer-screening-diagnosis-synopsis-european-breast-guidelines
Annals of Internal Medicine; Holger J. Schünemann, et al

Nov 30th, 2019 - This synopsis of the European Breast Guidelines provides recommendations regarding organized screening programs for women aged 40 to 75 years who are at average risk. The recommendations address digital mammography screening and the addition of hand-held ultrasonography, automated breast ultrasonography, or magnetic resonance imaging compared with mammography alone. The recommendations also dis...

Quantitative Blood Loss in Obstetric Hemorrhage - ACOG COMMITTEE OPINION, Number 794
https://journals.lww.com/greenjournal/Fulltext/2019/12000/Quantitative_Blood_Loss_in_Obstetric_Hemorrhage_.40.aspx
Obstetrics & Gynecology;

Nov 30th, 2019 - Postpartum hemorrhage causes approximately 11% of maternal deaths in the United States and is the leading cause of death that occurs on the day of birth. Importantly, 54–93% of maternal deaths due to obstetric hemorrhage may be preventable. Studies that have evaluated factors associated with identification and treatment of postpartum hemorrhage have found that imprecise health care provider est...

Pelvic Organ Prolapse ACOG Practice Bulletin, Number 214
https://journals.lww.com/greenjournal/Abstract/2019/11000/Pelvic_Organ_Prolapse__ACOG_Practice_Bulletin,.44.aspx
Obstetrics & Gynecology;

Nov 29th, 2019 - Pelvic organ prolapse (POP) is a common, benign condition in women. For many women it can cause vaginal bulge and pressure, voiding dysfunction, defecatory dysfunction, and sexual dysfunction, which may adversely affect quality of life. Women in the United States have a 13% lifetime risk of undergoing surgery for POP (1). Although POP can occur in younger women, the peak incidence of POP sympto...

Supplemental MRI Screening for Women with Extremely Dense Breast Tissue
https://www.nejm.org/doi/10.1056/NEJMoa1903986
NEJM Bakker MF, et al

Nov 27th, 2019 - Extremely dense breast tissue is a risk factor for breast cancer and limits the detection of cancer with mammography. Data are needed on the use of supplemental magnetic resonance imaging (MRI) to improve early detection and reduce interval breast cancers in such patients.

Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer
https://jamanetwork.com/journals/jamaoncology/article-abstract/2756224
JAMA Oncology; Mayadev JS, et al

Nov 26th, 2019 - Is immunotherapy after chemoradiotherapy in node-positive cervical cancer tolerable?

Study Finds Sexual Health Issues Are a Concern Among Majority of Women With Breast Cancer
https://ascopost.com/news/november-2019/study-finds-sexual-health-issues-are-a-concern-among-majority-of-women-with-breast-cancer/
ASCO Post; Doyle C

Nov 17th, 2019 - Endocrine therapy has been a lifesaver for women with estrogen receptor–positive breast cancer, but decreases in recurrence and cancer-related mortality have come with substantial side effects, according to data presented at the 2019 Supportive Care in Oncology Symposium.1 The results of a cross-sectional retrospective study have underscored genitourinary symptoms and sexual health concerns exp...

Depression in Children and Adolescents: Evaluation and Treatment
https://www.aafp.org/afp/2019/1115/p609.html
American Family Physician; Selph SS et al

Nov 16th, 2019 - he prevalence of major unipolar depression in children and adolescents is increasing in the United States. In 2016, approximately 5% of 12-year-olds and 17% of 17-year-olds reported experiencing a major depressive episode in the previous 12 months. Screening for depression in adolescents 12 years and older should be conducted annually using a validated instrument, such as the Patient Health Que...

Best, Worst, and Typical Cancer Survival: New Estimates Tool
https://www.medscape.com/viewarticle/921425
Medscape O'Brien K

Nov 14th, 2019 - "How much time have I got, Doc?" That's a question never far from the mind of most metastatic breast cancer patients. Unfortunately, accurate estimates are elusive. A new approach mitigates the difficulty of that tough task by offering not one but three estimates.

Risk-Adapted Starting Age of Screening for Relatives of Patients With Breast Cancer
https://jamanetwork.com/journals/jamaoncology/article-abstract/2755638
JAMA Oncology; Mukama T, et al

Nov 13th, 2019 - At what age should women with differing family histories of breast cancer start screening?

Is There a Difference in Breast Cancer Recurrence Rates After Surgery With Regional vs General Anesthesia?
https://ascopost.com/news/november-2019/is-there-a-difference-in-breast-cancer-recurrence-rates-after-surgery-with-regional-vs-general-anesthesia/
ASCO Post; Stenger M

Nov 11th, 2019 - In a trial reported in The Lancet, Sessler et al found no difference in breast cancer recurrence after surgery with regional anesthesia-analgesia using paravertebral block and propofol vs general anesthesia with the volatile anesthetic sevoflurane and opioid analgesia. They also found no difference in persistent incisional pain between approaches.

Top 10 Medical Innovations for 2020, According to Cleveland Clinic
https://www.medscape.com/viewarticle/920936
Medscape

Nov 9th, 2019 - A dual-acting osteoporosis drug, minimally invasive mitral valve surgery, and a new treatment for peanut allergies are among the medical advances that will significantly transform the medical field and improve care for patients in the coming year, according to the Cleveland Clinic's list of top 10 medical innovations for 2020.

PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets
https://ascopost.com/issues/november-10-2019/prima-trial-reports-benefit-with-niraparib-across-ovarian-cancer-subsets/
ASCO Post; Helwick C

Nov 9th, 2019 - In women with advanced ovarian cancer responding to first-line chemotherapy, maintenance therapy with the PARP inhibitor niraparib significantly reduced the risk of disease progression by 38% overall and by 60% in women with BRCA mutations. Even patients without a homologous recombination deficiency derived advantage from this treatment, in the phase III PRIMA/ENGOT-OV26/GOG-3012 trial presente...

Men With BRCA2 Should Be Screened for Prostate Cancer
https://www.medscape.com/viewarticle/921000
Medscape Davenport L

Nov 7th, 2019 - Men who carry the BRCA2 gene mutation, which is linked to breast and ovarian cancer, are at risk of developing aggressive prostate cancer and so should undergo regular prostate-specific antigen (PSA) testing, suggest findings from a major study.